Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of berberine to preparing medicine for treating acute myeloid leukemia

A technology for acute myeloid and leukemia, applied in the field of medicine, can solve problems such as the research gap of acute myeloid leukemia, and achieve the effects of low cost, small side effects and good apoptosis rate

Active Publication Date: 2015-11-11
长沙市中心医院
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the research on berberine in acute myeloid leukemia caused by FLT3 mutation is almost blank

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of berberine to preparing medicine for treating acute myeloid leukemia
  • Application of berberine to preparing medicine for treating acute myeloid leukemia
  • Application of berberine to preparing medicine for treating acute myeloid leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1. Morphological effects of berberine on the standard cell line MV-41 of refractory acute myeloid leukemia

[0025] The experimental materials used in this example are as follows: MV-41 cell line (refractory acute myeloid leukemia cells) was purchased from ATCC in the United States; Berberine (Berberine, content 98.5%) was purchased from Shaanxi Dadi Pharmaceutical Company, and the production batch number is 20111016; Cytarabine was purchased from Pfizer Pharmaceutical Co., Ltd.; DMEM medium was purchased from GIBCO; fetal bovine serum was purchased from Zhejiang Tianhang Biotechnology Co., Ltd.; NaHCO3 was purchased from Shanghai Jiuyi Chemical Reagent Co., Ltd., Cat.No.11810 -033; trypsin, EDTA, penicillin G sodium salt, and streptomycin sulfate were purchased from AMRESCO; absolute ethanol was purchased from Chongqing Chuandong Chemical Co., Ltd.; PBS was purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.; From German Leica company, the model is...

Embodiment 2

[0030] Embodiment 2, berberine to refractory acute myeloid leukemia standard cell line MV-41 half inhibitory concentration

[0031] The experimental materials used in this example are as follows: MTT (tetramethylazolazolium blue) reagent was purchased from Sigma Company; enzyme-linked immunoassay instrument was purchased from Bio-RAD Company. MV-41 cell line at 37°C, 5% CO 2 Subculture was carried out in an incubator with saturated humidity, and the cells were used for experiments when they were in the logarithmic growth phase.

[0032] Experimental method: prepare a single cell suspension with culture medium containing 10% fetal bovine serum, and use 2×10 per well 5 / mL inoculated in a 96-well culture plate with a volume of 100 μL per well, and then moved the culture plate into CO 2 in an incubator at 37 °C, 5% CO 2 and cultured for 24 hours under saturated humidity conditions. Remove the culture medium, then add berberine 0.9% sodium chloride aqueous solution and cytarab...

Embodiment 3

[0038] Example 3. Verification of the proliferative activity of berberine on the standard cell line MV-41 of refractory acute myeloid leukemia

[0039] According to Example 2, on the basis of preliminarily determining the half-maximum inhibitory concentration and time of berberine to MV-41, the selected concentration is 50 μg / ml, 100 μg / ml, 150 μg / ml and 200 μg / ml of berberine and the concentration is 100 μg / ml, 200 μg / ml, 400μg / ml Cytarabine acted on MV-41 cells for 24h, 48h and 72h respectively, and the inhibition rate was detected. The results are shown in Table 2.

[0040] Table 2, the inhibition rate (%) n=3 of different berberine effects on MV-41 cells at different times

[0041]

[0042] As can be seen from Table 2, as the concentration of berberine increased, its inhibitory rate to cells also increased significantly. When the berberine concentration was 50 μg / ml, the 24h inhibition rate was 61.61%; when the concentration increased to 200 μg / ml , the inhibition rat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of berberine to preparing medicine for treating acute myeloid leukemia. The application has the advantages that novel application of the berberine which is used as the medicine is developed, novel application is also provided for treating intractable acute myeloid leukemia, acute myeloid MV4-11 cells and acute myeloid leukemia cells separated from intractable patients are used as models, suppression effects can be realized by the berberine for the acute myeloid MV4-11 cells, cell cycles are arrested at G1 / G2 periods, the survival time of mice suffering from acute myeloid leukemia can be prolonged, and accordingly the berberine can be used as the novel medicine for treating the acute myeloid leukemia.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of berberine in the preparation of medicines for treating acute myeloid leukemia. Background technique [0002] Leukemia, also known as "blood cancer", is a malignant disease of hematopoietic tissues. It is characterized by malignant and unlimited proliferation of white blood cells in the bone marrow and other hematopoietic tissues, and then infiltrates various tissues and organs throughout the body, causing serious damage to the body. According to the maturity of the cells and the natural course of the disease, leukemia can be divided into two categories: acute leukemia and chronic leukemia. Acute leukemia is divided into two categories: acute lymphocytic leukemia and acute non-lymphocytic leukemia. Acute nonlymphocytic leukemia, also known as acute myeloid leukemia, is a type of disease formed by mutations in the karyotype of pluripotent stem cells or slight...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P35/02
Inventor 李杰平孙红武田志强杜方川滕永生杨励石哲
Owner 长沙市中心医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com